Abstract
BACKGROUND AND PURPOSE:
Medical cannabis may be effective treatment for refractory epilepsy. It is timely to seek users’ and potential users’ opinions in regard to its place in the management of epilepsy.
MATERIALS AND METHODS:
An online survey was administered to members of an epilepsy support organisation in Western Australia. Experience with cannabis for management of epilepsy was explored, along with desire to trial a particular pharmaceutical formulation(s).
RESULTS:
People with epilepsy (33/71) and carers (38/71) participated. Fifty-four participants indicated no experience with medical cannabis, although 35, mainly with inadequate response to prescription medicines, were willing to ask for a prescription. Concerns included difficulty accessing cannabis and high cost of this treatment. Tablets/capsules was the most acceptable dosage form for development.
CONCLUSION:
These findings suggest wide interest in trialling medical cannabis in individual cases of refractory epilepsy, despite the developing body of literature and some concerns about cost and procurement.
Crown Copyright © 2018. Published by Elsevier Ltd. All rights reserved.
KEYWORDS:
Epilepsy; Medical cannabis; Medicinal cannabis; Seizures; Survey
- PMID: 30396625
- DOI: 10.1016/j.ctcp.2018.08.003
-
LinkOut – more resources
